menu
    • menu

    Company profile for Memgen

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Memgen is a cancer immunotherapy company focused on creating drugs that harness the power of the immune system to cure cancer and other life-threatening diseases. Its first-in-class immune-oncology therapeutics are designed for the treatment of patients who do not respond to currently available therapeutic options. The Company’s lead product, MEM-288, is engineered to both selectively target cancer cells and supercharge the ...
    Memgen is a cancer immunotherapy company focused on creating drugs that harness the power of the immune system to cure cancer and other life-threatening diseases. Its first-in-class immune-oncology therapeutics are designed for the treatment of patients who do not respond to currently available therapeutic options. The Company’s lead product, MEM-288, is engineered to both selectively target cancer cells and supercharge the immune system through expression of two unique and powerful immune modulators: CD40 ligand (CD40L) and the powerful cytokine interferon beta.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MemgenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12 Greenway Plaza, Suite 1100, Houston, TX 77046, US
    Telephone
    Telephone
    +49-551-39-14189
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://memgen.uni-goettingen.de/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/memgen-llc/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Memgen Initiates Phase 1 Combo Trial of MEM-288 with Docetaxel
    Memgen Initiates Phase 1 Combo Trial of MEM-288 with Docetaxel

    25 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/25/3138854/0/en/Memgen-Announces-First-Patient-Dosed-in-Phase-1-Combination-Cohort-of-MEM-288-Plus-Docetaxel-in-Advanced-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    25 Aug 2025
    Share Share
    Memgen Announces Data on MEM-288 in Advanced/Metastatic NSCLC
    Memgen Announces Data on MEM-288 in Advanced/Metastatic NSCLC

    06 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230606005291/en

    BUSINESSWIRE
    06 Jun 2023
    Share Share
    Memgen Reports Results From Its First-In-Human Trial of MEM-288 in Solid Tumors
    Memgen Reports Results From Its First-In-Human Trial of MEM-288 in Solid Tumors

    30 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221130005841/en

    BUSINESSWIRE
    30 Nov 2022
    Share Share
    Memgen Appoints Kevin M. Coveney as Chief Financial Officer
    Memgen Appoints Kevin M. Coveney as Chief Financial Officer

    17 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211117005439/en

    BUSINESSWIRE
    17 Nov 2021
    Share Share
    Memgen Announces Research to Be Presented at 2020 (AACR) Meeting
    Memgen Announces Research to Be Presented at 2020 (AACR) Meeting

    02 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/memgen-announces-research-to-be-presented-at-2020-american-association-of-cancer-research-aacr-meeting-301068860.html

    PRNEWSWIRE
    02 Jun 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search